Literature DB >> 23943853

Human angiotensinogen +11525 C/A polymorphism modulates its gene expression through microRNA binding.

Brahmaraju Mopidevi1, Madhusudhan Ponnala, Ashok Kumar.   

Abstract

Hypertension is a serious risk factor for cardiovascular disease. Like other complex disease, hypertension is caused by a combination of genetic and environmental factors. The renin-angiotensin system plays an important role in the regulation of blood pressure. Angiotensinogen (AGT) gene is associated with essential hypertension in Caucasians, Japanese, and Asian-Indian subjects. AGT gene may also be associated with cardiac hypertrophy, coronary atherosclerosis, and microangiopathy related cerebral damage. Human AGT gene has a C/A polymorphism at nucleoside 11525 (rs7079) that is located in the 3'-untranslated region (3'-UTR) and is modestly associated with increased blood pressure. We show here that miR-31 and miR-584 bind strongly to the hAGT 3'-UTR containing 11525C allele compared with 11525A allele. We also show that transfection of miR-31 and miR-584 downregulates the hAGT mRNA and protein levels in human liver cells. These studies may provide new therapeutic approach to reduce hypertension.

Entities:  

Keywords:  3′-untranslated region; blood pressure regulation; human angiotensinogen gene; hypertension; miRNA; rs7079; single nucleotide polymorphism

Mesh:

Substances:

Year:  2013        PMID: 23943853      PMCID: PMC3798777          DOI: 10.1152/physiolgenomics.00056.2013

Source DB:  PubMed          Journal:  Physiol Genomics        ISSN: 1094-8341            Impact factor:   3.107


  28 in total

1.  Transgenic mice with -6A haplotype of the human angiotensinogen gene have increased blood pressure compared with -6G haplotype.

Authors:  Sudhir Jain; Andrej Tillinger; Brahmaraju Mopidevi; Varunkumar G Pandey; Chetankumar K Chauhan; Steven N Fiering; Soren Warming; Ashok Kumar
Journal:  J Biol Chem       Date:  2010-10-26       Impact factor: 5.157

2.  MicroRNA genes are transcribed by RNA polymerase II.

Authors:  Yoontae Lee; Minju Kim; Jinju Han; Kyu-Hyun Yeom; Sanghyuk Lee; Sung Hee Baek; V Narry Kim
Journal:  EMBO J       Date:  2004-09-16       Impact factor: 11.598

3.  Prehypertension, racial prevalence and its association with risk factors: Analysis of the REasons for Geographic And Racial Differences in Stroke (REGARDS) study.

Authors:  Stephen P Glasser; Suzanne Judd; Jan Basile; Dan Lackland; Jewell Halanych; Mary Cushman; Ronald Prineas; Virginia Howard; George Howard
Journal:  Am J Hypertens       Date:  2010-09-23       Impact factor: 2.689

4.  LNA-mediated microRNA silencing in non-human primates.

Authors:  Joacim Elmén; Morten Lindow; Sylvia Schütz; Matthew Lawrence; Andreas Petri; Susanna Obad; Marie Lindholm; Maj Hedtjärn; Henrik Frydenlund Hansen; Urs Berger; Steven Gullans; Phil Kearney; Peter Sarnow; Ellen Marie Straarup; Sakari Kauppinen
Journal:  Nature       Date:  2008-03-26       Impact factor: 49.962

Review 5.  Investing in high blood pressure research: a national institutes of health perspective.

Authors:  Zorina S Galis; Terry Thrasher; Diane M Reid; Dennis V Stanley; Young S Oh
Journal:  Hypertension       Date:  2013-02-25       Impact factor: 10.190

6.  Angiotensinogen gene haplotype is associated with the prevalence of Japanese non-alcoholic steatohepatitis.

Authors:  Masafumi Ono; Tsunehiro Ochi; Kensuke Munekage; Mitsunari Ogasawara; Akira Hirose; Yasuko Nozaki; Masaya Takahashi; Nobuto Okamoto; Toshiji Saibara
Journal:  Hepatol Res       Date:  2011-10-11       Impact factor: 4.288

7.  A population association study of angiotensinogen polymorphisms and haplotypes with left ventricular phenotypes.

Authors:  Laura J Rasmussen-Torvik; Kari E North; C Charles Gu; Cora E Lewis; Jemma B Wilk; Aravinda Chakravarti; Yen-Pei C Chang; Michael B Miller; Na Li; Richard B Devereux; Donna K Arnett
Journal:  Hypertension       Date:  2005-11-14       Impact factor: 10.190

8.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321

9.  Angiotensinogen promoter B-haplotype associated with cerebral small vessel disease enhances basal transcriptional activity.

Authors:  Helena Schmidt; Yurii S Aulchenko; Natascha Schweighofer; Reinhold Schmidt; Sasa Frank; Gerhard M Kostner; Erwin Ott; Cornelia van Duijn
Journal:  Stroke       Date:  2004-10-07       Impact factor: 7.914

10.  Antagonism of microRNA-122 in mice by systemically administered LNA-antimiR leads to up-regulation of a large set of predicted target mRNAs in the liver.

Authors:  Joacim Elmén; Morten Lindow; Asli Silahtaroglu; Mads Bak; Mette Christensen; Allan Lind-Thomsen; Maj Hedtjärn; Jens Bo Hansen; Henrik Frydenlund Hansen; Ellen Marie Straarup; Keith McCullagh; Phil Kearney; Sakari Kauppinen
Journal:  Nucleic Acids Res       Date:  2007-12-23       Impact factor: 16.971

View more
  10 in total

1.  Polymorphism in miR-31 and miR-584 binding site in the angiotensinogen gene differentially influences body fat distribution in both sexes.

Authors:  Jan Machal; Jan Novak; Renata Hezova; Filip Zlamal; Anna Vasku; Ondrej Slaby; Julie Bienertova-Vasku
Journal:  Genes Nutr       Date:  2015-08-26       Impact factor: 5.523

Review 2.  Hypertensive epigenetics: from DNA methylation to microRNAs.

Authors:  J Wang; L Gong; Y Tan; R Hui; Y Wang
Journal:  J Hum Hypertens       Date:  2015-01-29       Impact factor: 3.012

3.  A polymorphism in intron I of the human angiotensinogen gene (hAGT) affects binding by HNF3 and hAGT expression and increases blood pressure in mice.

Authors:  Brahmaraju Mopidevi; Meenakshi K Kaw; Indu Sivankutty; Sudhir Jain; Sravan Kumar Perla; Ashok Kumar
Journal:  J Biol Chem       Date:  2019-06-14       Impact factor: 5.157

4.  A novel role for miR-133a in centrally mediated activation of the renin-angiotensin system in congestive heart failure.

Authors:  Neeru M Sharma; Shyam S Nandi; Hong Zheng; Paras K Mishra; Kaushik P Patel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2017-03-10       Impact factor: 4.733

Review 5.  Novel insights into miRNA in lung and heart inflammatory diseases.

Authors:  Amit Kishore; Jana Borucka; Jana Petrkova; Martin Petrek
Journal:  Mediators Inflamm       Date:  2014-05-27       Impact factor: 4.711

6.  A functional variant in ST2 gene is associated with risk of hypertension via interfering MiR-202-3p.

Authors:  Fangqin Wu; Lu Li; Qiang Wen; Jinhua Yang; Zhuyue Chen; Peng Wu; Meian He; Xiaomin Zhang; Tangchun Wu; Longxian Cheng
Journal:  J Cell Mol Med       Date:  2017-01-25       Impact factor: 5.310

Review 7.  Non-coding RNAs and hypertension-unveiling unexpected mechanisms of hypertension by the dark matter of the genome.

Authors:  Kazuo Murakami
Journal:  Curr Hypertens Rev       Date:  2015

8.  A Genome-Wide Association Study of Idiopathic Dilated Cardiomyopathy in African Americans.

Authors:  Huichun Xu; Gerald W Dorn; Amol Shetty; Ankita Parihar; Tushar Dave; Shawn W Robinson; Stephen S Gottlieb; Mark P Donahue; Gordon F Tomaselli; William E Kraus; Braxton D Mitchell; Stephen B Liggett
Journal:  J Pers Med       Date:  2018-02-26

9.  Transcriptome analysis of arterial and venous circulating miRNAs during hypertension.

Authors:  Ling Jin; Min Li; Hao Wang; Zhongnan Yin; Li Chen; Yang Zhou; Yongzheng Han; Qinghua Cui; Yuan Zhou; Lixiang Xue
Journal:  Sci Rep       Date:  2021-02-10       Impact factor: 4.379

10.  A new model of the mechanism underlying lead poisoning: SNP in miRNA target region influence the AGT expression level.

Authors:  Yu Wu; Miaomiao Wang; Jinlong Zhang; Na Sun; Chunping Li
Journal:  Hereditas       Date:  2019-01-26       Impact factor: 3.271

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.